Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
The Oncologist
|
May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica Bauman, et al.
American Journal of Clinical Oncology
|
February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
Roger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2012
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
D Neil Hayes, Amy S Lucas, Tawee Tanvetyanon, et al.
The Lancet. Oncology
|
March 22, 2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
Martin Fassnacht, Alfredo Berruti, Eric Baudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group
Shanthi Marur, Shuli Li, Anthony J Cmelak, et al.
JAMA Oncology
|
November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial
Lillian L Siu, Caroline Even, Ricard Mesía, et al.
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
JCO Oncology Practice
|
July 9, 2021
Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform
Richard L Martin, Michael J Grant, Stephen Kimani, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2017
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, et al.
The Oncologist
|
May 10, 2022
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
Xiuning Le, Christina Baik, Jessica Bauman, et al.
American Journal of Clinical Oncology
|
February 21, 2018
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study
Roger B Cohen, Jean-Pierre Delord, Toshihiko Doi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2012
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements
D Neil Hayes, Amy S Lucas, Tawee Tanvetyanon, et al.
The Lancet. Oncology
|
March 22, 2015
Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study
Martin Fassnacht, Alfredo Berruti, Eric Baudin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2016
E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group
Shanthi Marur, Shuli Li, Anthony J Cmelak, et al.
JAMA Oncology
|
November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial
Lillian L Siu, Caroline Even, Ricard Mesía, et al.
The Oncologist
|
May 7, 2014
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel
Douglas B Johnson, Kimberly H Dahlman, Jared Knol, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2018
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P Zandberg, Alain P Algazi, Antonio Jimeno, et al.
JCO Oncology Practice
|
July 9, 2021
Forming the Hematology-Oncology Collaborative Videoconferencing (CO-VID) Learning Initiative: Experiential Lessons Learned From a Novel Trainee-Led Multidisciplinary Virtual Learning Platform
Richard L Martin, Michael J Grant, Stephen Kimani, et al.
Page
of 8